My three major take away on the report:
- In patients who had previously received 1-2 biologics, a single infusion of 2 million MPC/kg resulted in 55% and 36% ACR50 and ACR70 responses, respectively, compared with 11% and 0% of placebo treated patients, and in 91% of patients achieving the minimum clinically important improvement in physical function, defined as a reduction of at least -0.22 in the HAQ-DI, compared with 33% placebo treated patients
- Given the large market opportunity, Mesoblast's Tier 1 product candidate, MPC-300-IV, is well-positioned to advance through a strategic partnership into Phase 3 development for biologic refractory rheumatoid arthritis
- Major advances in the treatment of RA using biologic agents have resulted in a $15 billion global market in 2015, which is projected to grow to over $18 billion in 2024. Over two million patients were treated for RA in the United States alone in 2015, with three million more people in the five major European markets and Japan.
- Forums
- ASX - By Stock
- Ann: Presentation On Mesoblast RA P2 Trial Results-MSB.AX
My three major take away on the report: In patients who had...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.01 |
Change
-0.065(6.07%) |
Mkt cap ! $1.147B |
Open | High | Low | Value | Volume |
$1.05 | $1.05 | 99.5¢ | $9.449M | 9.298M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 64999 | $1.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.02 | 64541 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 64999 | 1.005 |
7 | 58759 | 1.000 |
13 | 162397 | 0.995 |
23 | 402743 | 0.990 |
10 | 194198 | 0.985 |
Price($) | Vol. | No. |
---|---|---|
1.020 | 64541 | 3 |
1.025 | 71041 | 4 |
1.030 | 154979 | 5 |
1.035 | 90341 | 5 |
1.040 | 32541 | 1 |
Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online